Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109640 | 0.87 | ALDH1A1 (0.70) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL331031 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL11215746 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL8803655 | 0.78 | ALDH1A1 (0.67) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL715694 | 0.78 | ALDH1A1 (0.70) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| SCHEMBL10148178 | 0.78 | ALDH1A1 (0.61) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| Malathion SCHEMBL3705116 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| Malathion SCHEMBL124812 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| Malathion SCHEMBL27358 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15TSHRTDP1 | |
| Malathion SCHEMBL21693725 | 0.76 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158893-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2015-06-11 | — | — | US | disclosed |
| US-8957238-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2015-02-17 | — | — | US | disclosed |
| US-8536155-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2013-09-17 | — | — | US | disclosed |
| US-20120010175-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (IE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010175-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (IE) | 2012-01-12 | — | — | US | disclosed |
| US-8039657-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2011-10-18 | — | — | US | disclosed |
| US-7977324-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2011-07-12 | — | — | US | disclosed |
| US-7560445-B2 | Process for preparing malathion for pharmaceutical use | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2009-07-14 | — | — | US | disclosed |
| US-20090124823-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2009-05-14 | — | — | US | disclosed |
| US-20090124822-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158893-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885CYP3A4 55/4885ALOX15 401/4885 |
| US-20090124823-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885CYP3A4 55/4885ALOX15 401/4885 |
| US-20090124822-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885CYP3A4 55/4885ALOX15 401/4885 |
| US-20120010175-A1 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE | MSMO1, DDO, DCPS | ALDH1A1 1780/4885CYP3A4 55/4885ALOX15 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.